Jazz Pharmaceuticals plc — Director's Dealing 2019

Aug 14, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2019-08-12

Reporting Person: Treacy Paul (SVP, Technical Operations)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-08-12	Ordinary Shares	S	4371	$137.403	Disposed	16418	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Ordinary Shares	106	Indirect

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $137.4015 to $137.4322, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.

F2: Includes 140 ordinary shares acquired under a Section 423 Employee Stock Purchase Plan on May 31, 2019.

F3: Represents ordinary shares purchased by Irish Pensions Trust Limited, as trustee for and on behalf of the Reporting Person, as sole beneficiary, pursuant to an Irish Revenue approved profit share scheme on March 15, 2019 in a transaction exempt under Rule 16b-3(c).